x min read

Upbeat Stocks At Street: Chiquita Brands International Inc. (NYSE:CQB), Antero Resources Corporation (NYSE:AR), Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Upbeat Stocks At Street: Chiquita Brands International Inc. (NYSE:CQB), Antero Resources Corporation (NYSE:AR), Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Written by
Ryan Mitchell
Published on
October 30, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Chiquita Brands International Inc. (NYSE:CQB) as well as the Cutrale-Safra group released that a definitive merger contract, under which Cutrale-Safra will purchase all outstanding common shares of Chiquita for $14.50 per share in cash. Chiquita Brands International Inc. (NYSE:CQB) stock hit highest price at $14.42, beginning with a price of $14.42 to the closed at 14.39 by a decrease of remains unchanged with a day range of $14.385-$14.42. The total market capitalization remained 675.8 Million, total volume of 1.33 Million shares held in the session was surprisingly higher than its average volume of 1068.10 shares.Antero Resources Corporation (NYSE:AR) commencement of the Antero Midstream Partners LP initial public offering or IPO of 37.5M common units, representing limited partner interests in the alliance, at an anticipated IPO price between $19 and $21 per unit, according to a registration statement on Form S-1 previously filed with the U.S. SEC. Shares of Antero Resources Corporation (NYSE:AR) opened at $50.59 with 262.05 million outstanding shares and hit to its highest price of $51.50 during the day and finally closed at $50.83 by scoring 1.52%. In the whole session, it traded on volume of 948062 shares, which turned higher than its average volume.Sarepta Therapeutics, Inc. (NASDAQ:SRPT) declared that FDA asked for additional data that they are need as part of the New Drug Application or NDA submission for Eteplirsen, comprising the results from an independent assessment of dystrophin images and the 168-week clinical data from study 202. As well, FDA requested for more specific data, including a minimum duration of safety in new patients uncovered to eteplirsen, patient-level natural history data and MRI data from a recent study conducted by an independent academic group. On the other consideration, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) begun last trade with a price of $15.03 and throughout the trading session climbed at $15.25. The day-trade ended with an increase of 0.46% to closed at $15.19.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.

Recommended for You